Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Parameters of markov model

From: Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia

Parameters

Value

Sensitivity range

Distribution

Source

Relative Risk

0. 9,931,201

0.989711—0.996541

Beta

 

Discount Rate

0.05

0.03–0.07

Beta

IETS (17)

Effect Controlled

1.0

1.0

  

Effect Uncontrolled

0.0

0.0

  

Effect Death

0.0

0.0

  

Cost of Controlled*

423.87 (939.17)

72.59—492.44

Gamma

 

Cost of Uncontrolled With Nephroprotection*

515.25 (1,293.73)

58.45—608.90

Gamma

 

Cost of Uncontrolled Without Nephroprotection*

521.01 (1,032.85)

79.24—659.07

Gamma

 

N

1,000

   
  1. *The standard deviation (SD) of total annual costs are shown in parentheses ()
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us